Form 8-K SYNERGY PHARMACEUTICALS, For: May 09
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Tech stocks pull Wall Street lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Synergy Pharma (SGYP) Misses Q1 EPS Views; Offers Corp. Update
May 10, 2016 4:36 PM EDTSynergy Pharma (NASDAQ: SGYP) reported Q1 EPS of ($0.51), $0.28 worse than the analyst estimate of ($0.23).
2016 is off to a strong and promising start for Synergy, highlighted by the U.S. Food and Drug Administration (FDA) acceptance of our first new drug application (NDA) for plecanatide in chronic idiopathic constipation (CIC), said Gary S. Jacob, Chairman and Chief Executive Officer of Synergy Pharmaceuticals. We continued to expand the utility and value of our uroguanylin-based platform technology while significantly strengthening our overall financial position. Moving forward, we believe we are well positioned to successfully execute on key... More
